4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-25-041214
President & Immunovant CEO sold 200,000 shares at $20.22 ($4,044,000)
- President & Immunovant CEO acquired 200,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2025-11-07 | Option exercise 10b5-1 | +200,000 | $3.85 | $770,000 | 1,704,959 | D: show line 1 in the form |
| Venker Eric President & Immunovant CEO | 2025-11-07 | Sale 10b5-1 | −200,000 | $20.22 | $4,044,000 | 1,504,959 | D: show line 2 in the form |
| Open-market sales · 200,000 sh · avg $20.22 · $4,044,000 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2025-11-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | $20.22 | $4,044,000 | 6,076,523 | D: show line 3 in the form |
Loading xslF345X05/form4.xml…